<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="11" family="Helvetica-Black,Bold" color="#ffffff"/>
	<fontspec id="font1" size="8" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font2" size="8" family="AkzidenzGroteskBE-Md,Bold" color="#000000"/>
	<fontspec id="font3" size="8" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font4" size="8" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font5" size="2" family="AkzidenzGroteskBE" color="#ffffff"/>
	<fontspec id="font6" size="15" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font7" size="16" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font8" size="12" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font9" size="6" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font10" size="8" family="AkzidenzGroteskBE-It,Italic" color="#000000"/>
	<fontspec id="font11" size="11" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font12" size="9" family="AkzidenzGroteskBE-Md,Bold" color="#000000"/>
	<fontspec id="font13" size="9" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font14" size="9" family="AkzidenzGroteskBE-It,Italic" color="#000000"/>
<text top="85" left="477" width="78" height="10" font="font0" id="p1_t1" reading_order_no="1" segment_no="1" tag_type="title">Open Access<a href="http://www.biomedcentral.com/info/about/charter/"><b>Open Access</b></a></text>
<text top="42" left="311" width="245" height="7" font="font1" id="p1_t2" reading_order_no="0" segment_no="0" tag_type="text">Available online http://breast-cancer-research.com/content/7/6/R940<b>Available online</b></text>
<text top="735" left="569" width="19" height="8" font="font4" id="p1_t3" reading_order_no="77" segment_no="24" tag_type="text">R940</text>
<text top="85" left="57" width="9" height="2" font="font5" id="p1_t4" reading_order_no="3" segment_no="2" tag_type="title">Vol 7 No 6</text>
<text top="85" left="57" width="103" height="14" font="font6" id="p1_t5" reading_order_no="2" segment_no="2" tag_type="title">Research article</text>
<text top="102" left="57" width="492" height="14" font="font7" id="p1_t6" reading_order_no="4" segment_no="3" tag_type="title">Targeted therapy against Bcl-2-related proteins in breast cancer</text>
<text top="120" left="57" width="35" height="14" font="font7" id="p1_t7" reading_order_no="5" segment_no="3" tag_type="title">cells<b>Targeted therapy against Bcl-2-related proteins in breast cancer </b></text>
<text top="137" left="57" width="411" height="12" font="font8" id="p1_t8" reading_order_no="6" segment_no="4" tag_type="text">Manabu Emi 1 , Ryungsa Kim 2 , Kazuaki Tanabe 1 , Yoko Uchida 1 and Tetsuya Toge 1<b>cells</b></text>
<text top="171" left="57" width="438" height="7" font="font3" id="p1_t9" reading_order_no="7" segment_no="5" tag_type="text">1 Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan</text>
<text top="180" left="57" width="465" height="8" font="font3" id="p1_t10" reading_order_no="8" segment_no="6" tag_type="text">2 International Radiation Information Center, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan</text>
<text top="199" left="57" width="206" height="7" font="font3" id="p1_t11" reading_order_no="9" segment_no="7" tag_type="text">Corresponding author: Ryungsa Kim, rkim@hiroshima-u.ac.jp</text>
<text top="217" left="57" width="490" height="7" font="font3" id="p1_t12" reading_order_no="10" segment_no="8" tag_type="text">Received: 2 Feb 2005 Revisions requested: 3 Mar 2005 Revisions received: 25 Aug 2005 Accepted: 31 Aug 2005 Published: 28 Sep 2005</text>
<text top="235" left="57" width="243" height="7" font="font10" id="p1_t13" reading_order_no="11" segment_no="9" tag_type="text">Breast Cancer Research 2005, 7 :R940-R952 (DOI 10.1186/bcr1323)</text>
<text top="245" left="57" width="260" height="7" font="font3" id="p1_t14" reading_order_no="12" segment_no="10" tag_type="text">This article is online at: http://breast-cancer-research.com/content/7/6/R940</text>
<text top="255" left="57" width="166" height="7" font="font3" id="p1_t15" reading_order_no="13" segment_no="11" tag_type="text">Â© 2005 Emi et al .; licensee BioMed Central Ltd.</text>
<text top="265" left="57" width="495" height="7" font="font3" id="p1_t16" reading_order_no="14" segment_no="12" tag_type="text">This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/</text>
<text top="275" left="57" width="426" height="7" font="font3" id="p1_t17" reading_order_no="15" segment_no="12" tag_type="text">2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</text>
<text top="305" left="57" width="43" height="10" font="font11" id="p1_t18" reading_order_no="16" segment_no="13" tag_type="title">Abstract</text>
<text top="325" left="57" width="240" height="8" font="font12" id="p1_t19" reading_order_no="17" segment_no="14" tag_type="text">Introduction Bcl-2 and Bcl-xL confer resistance to apoptosis,</text>
<text top="336" left="57" width="240" height="8" font="font13" id="p1_t20" reading_order_no="18" segment_no="14" tag_type="text">thereby reducing the effectiveness of chemotherapy. We</text>
<text top="346" left="57" width="240" height="8" font="font13" id="p1_t21" reading_order_no="19" segment_no="14" tag_type="text">examined the relationship between the expression of Bcl-2 and</text>
<text top="357" left="57" width="240" height="8" font="font13" id="p1_t22" reading_order_no="20" segment_no="14" tag_type="text">Bcl-xL and chemosensitivity of breast cancer cells, with the aim</text>
<text top="367" left="57" width="151" height="8" font="font13" id="p1_t23" reading_order_no="21" segment_no="14" tag_type="text">of developing specific targeted therapy.</text>
<text top="388" left="57" width="240" height="8" font="font12" id="p1_t24" reading_order_no="22" segment_no="16" tag_type="text">Methods Four human breast cancer cell lines were examined,</text>
<text top="399" left="57" width="240" height="8" font="font13" id="p1_t25" reading_order_no="23" segment_no="16" tag_type="text">and the effects of antisense (AS) Bcl-2 and AS Bcl-xL<i>Breast Cancer Research</i></text>
<text top="409" left="57" width="240" height="8" font="font13" id="p1_t26" reading_order_no="24" segment_no="16" tag_type="text">phosphorothioate oligodeoxynucleotides (ODNs) on</text>
<text top="420" left="57" width="198" height="8" font="font13" id="p1_t27" reading_order_no="25" segment_no="16" tag_type="text">chemosensitivity were tested in vitro and<b>7</b></text>
<text top="420" left="262" width="35" height="8" font="font14" id="p1_t28" reading_order_no="26" segment_no="16" tag_type="text">in vivo .</text>
<text top="430" left="57" width="240" height="8" font="font13" id="p1_t29" reading_order_no="27" segment_no="16" tag_type="text">Chemosensitivity was evaluated by the MTT (3-(4,5-<a href="http://breast-cancer-research.com/content/7/6/R940">This article is online at: http://breast-cancer-research.com/content/7/6/R940</a></text>
<text top="441" left="57" width="240" height="8" font="font13" id="p1_t30" reading_order_no="28" segment_no="16" tag_type="text">dimethylthiazol-2-yl)-2,5-diphenyl-2 H -tetrazolium bromide)</text>
<text top="451" left="57" width="240" height="8" font="font13" id="p1_t31" reading_order_no="29" segment_no="16" tag_type="text">assay, and the antitumor effect was assessed in vivo by the<i> et al</i></text>
<text top="462" left="57" width="208" height="8" font="font13" id="p1_t32" reading_order_no="30" segment_no="16" tag_type="text">success of xenograft transplantation into athymic mice.</text>
<text top="483" left="57" width="241" height="8" font="font12" id="p1_t33" reading_order_no="31" segment_no="17" tag_type="text">Results Treatment with AS Bcl-2 and Bcl-xL ODNs resulted in<a href="http://creativecommons.org/licenses/by/2.0"> (http://creativecommons.org/licenses/by/</a></text>
<text top="493" left="57" width="240" height="8" font="font13" id="p1_t34" reading_order_no="32" segment_no="17" tag_type="text">a sequence-specific decrease in protein expression, compared<a href="http://creativecommons.org/licenses/by/2.0">2.0),</a> which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</text>
<text top="504" left="57" width="240" height="8" font="font13" id="p1_t35" reading_order_no="33" segment_no="17" tag_type="text">with controls. Treatment of BT-474, ZR-75-1, and MDA-MB-<b>Abstract</b></text>
<text top="514" left="57" width="240" height="8" font="font13" id="p1_t36" reading_order_no="34" segment_no="17" tag_type="text">231 cells with AS Bcl-2 increased chemosensitivity to<b>Introduction</b></text>
<text top="325" left="315" width="240" height="8" font="font13" id="p1_t37" reading_order_no="35" segment_no="15" tag_type="text">doxorubicin (DOX), mitomycin C (MMC), paclitaxel (TXL), and</text>
<text top="336" left="315" width="241" height="8" font="font13" id="p1_t38" reading_order_no="36" segment_no="15" tag_type="text">docetaxel (TXT). Transfection of the Bcl-2 gene into MDA-MB-</text>
<text top="346" left="315" width="241" height="8" font="font13" id="p1_t39" reading_order_no="37" segment_no="15" tag_type="text">453 cells decreased sensitivity to DOX and MMC. Treatment of</text>
<text top="357" left="315" width="241" height="8" font="font13" id="p1_t40" reading_order_no="38" segment_no="15" tag_type="text">MDA-MB-231, BT-474, and ZR-75-1 cells with AS Bcl-xL</text>
<text top="367" left="315" width="240" height="8" font="font13" id="p1_t41" reading_order_no="39" segment_no="15" tag_type="text">increased chemosensitivity to DOX, MMC and taxanes to a</text>
<text top="378" left="315" width="240" height="8" font="font13" id="p1_t42" reading_order_no="40" segment_no="15" tag_type="text">smaller extent than AS Bcl-2 . This occurred in the setting of<b>Methods</b></text>
<text top="388" left="315" width="240" height="8" font="font13" id="p1_t43" reading_order_no="41" segment_no="15" tag_type="text">increased Bax and cleaved poly(ADP-ribose) polymerase, as</text>
<text top="399" left="315" width="241" height="8" font="font13" id="p1_t44" reading_order_no="42" segment_no="15" tag_type="text">well as decreased Bcl-2 and pAkt. AS Bcl-2 ODNs induced</text>
<text top="409" left="315" width="240" height="8" font="font13" id="p1_t45" reading_order_no="43" segment_no="15" tag_type="text">splenomegaly in association with increased serum IL-12, which<i>Bcl-2 </i></text>
<text top="420" left="315" width="240" height="8" font="font13" id="p1_t46" reading_order_no="44" segment_no="15" tag_type="text">was attenuated by methylation of the CpG motifs of AS Bcl-2 ;</text>
<text top="430" left="315" width="240" height="8" font="font13" id="p1_t47" reading_order_no="45" segment_no="15" tag_type="text">however, methylated CpG failed to negate the increased<i>Bcl-xL</i></text>
<text top="441" left="315" width="240" height="8" font="font13" id="p1_t48" reading_order_no="46" segment_no="15" tag_type="text">antitumor effect of AS Bcl-2 . Bcl-2 and Bcl-xL, to a smaller</text>
<text top="451" left="315" width="240" height="8" font="font13" id="p1_t49" reading_order_no="47" segment_no="15" tag_type="text">extent, are major determinants of chemosensitivity in breast</text>
<text top="462" left="315" width="48" height="8" font="font13" id="p1_t50" reading_order_no="48" segment_no="15" tag_type="text">cancer cells.<i>in vitro </i></text>
<text top="493" left="315" width="241" height="8" font="font12" id="p1_t51" reading_order_no="49" segment_no="18" tag_type="text">Conclusion Targeted therapy against Bcl-2 protein with the use</text>
<text top="504" left="315" width="241" height="8" font="font13" id="p1_t52" reading_order_no="50" segment_no="18" tag_type="text">of AS ODNs might enhance the effects of chemotherapy in<i>in vivo</i></text>
<text top="514" left="315" width="105" height="8" font="font13" id="p1_t53" reading_order_no="51" segment_no="18" tag_type="text">patients with breast cancer.</text>
<text top="564" left="57" width="64" height="10" font="font11" id="p1_t54" reading_order_no="52" segment_no="19" tag_type="title">Introduction</text>
<text top="575" left="57" width="240" height="9" font="font13" id="p1_t55" reading_order_no="53" segment_no="21" tag_type="text">Bcl-2 and Bcl-xL proteins are inhibitors of the mitochondrial</text>
<text top="587" left="57" width="240" height="9" font="font13" id="p1_t56" reading_order_no="54" segment_no="21" tag_type="text">apoptosis pathway; they exert their action by blocking their<i>H</i></text>
<text top="599" left="57" width="240" height="9" font="font13" id="p1_t57" reading_order_no="55" segment_no="21" tag_type="text">proapoptotic counterparts, including Bid and Bax, thereby</text>
<text top="611" left="57" width="240" height="9" font="font13" id="p1_t58" reading_order_no="56" segment_no="21" tag_type="text">preventing the release of cytochrome c and the activation of</text>
<text top="622" left="57" width="240" height="9" font="font13" id="p1_t59" reading_order_no="57" segment_no="21" tag_type="text">caspase [1,2]. Bcl-xL shows remarkable homology to Bcl-2<i>in vivo </i></text>
<text top="634" left="57" width="240" height="9" font="font13" id="p1_t60" reading_order_no="58" segment_no="21" tag_type="text">and inhibits apoptosis as effectively as Bcl-2 in some cells.</text>
<text top="646" left="57" width="240" height="9" font="font13" id="p1_t61" reading_order_no="59" segment_no="21" tag_type="text">Furthermore, Bcl-xL is capable of preventing cell death when</text>
<text top="658" left="57" width="240" height="9" font="font13" id="p1_t62" reading_order_no="60" segment_no="21" tag_type="text">Bcl-2 fails to do so, suggesting that these proteins exert inde-<b>Results</b></text>
<text top="669" left="57" width="240" height="9" font="font13" id="p1_t63" reading_order_no="61" segment_no="21" tag_type="text">pendent effects on the mitochondrial apoptotic pathway [3].</text>
<text top="681" left="57" width="240" height="9" font="font13" id="p1_t64" reading_order_no="62" segment_no="21" tag_type="text">Given that Bcl-2 and Bcl-xL are capable of inhibiting antican-<i>Bcl-2 </i></text>
<text top="564" left="315" width="240" height="9" font="font13" id="p1_t65" reading_order_no="63" segment_no="20" tag_type="text">cer drug-induced apoptosis, which is mediated by the voltage-</text>
<text top="575" left="315" width="240" height="9" font="font13" id="p1_t66" reading_order_no="64" segment_no="20" tag_type="text">dependent anion channel (VDAC) in the outer mitochondrial<i>Bcl-xL </i></text>
<text top="587" left="315" width="240" height="9" font="font13" id="p1_t67" reading_order_no="65" segment_no="20" tag_type="text">membrane, overexpression of Bcl-2 and Bcl-xL might confer</text>
<text top="599" left="315" width="240" height="9" font="font13" id="p1_t68" reading_order_no="66" segment_no="20" tag_type="text">resistance to chemotherapy [4]. In fact, overexpression of Bcl-</text>
<text top="611" left="315" width="241" height="9" font="font13" id="p1_t69" reading_order_no="67" segment_no="20" tag_type="text">2 and Bcl-xL is observed in several cancers, including hema-</text>
<text top="622" left="315" width="240" height="9" font="font13" id="p1_t70" reading_order_no="68" segment_no="20" tag_type="text">tologic malignancies, as well as a range of solid tumors, includ-</text>
<text top="634" left="315" width="240" height="9" font="font13" id="p1_t71" reading_order_no="69" segment_no="20" tag_type="text">ing nasopharyngeal, colorectal, prostate, and breast cancer<i>Bcl-2 </i></text>
<text top="646" left="315" width="21" height="9" font="font13" id="p1_t72" reading_order_no="70" segment_no="20" tag_type="text">[5-7].</text>
<text top="669" left="315" width="240" height="9" font="font13" id="p1_t73" reading_order_no="71" segment_no="22" tag_type="text">Antisense oligodeoxynucleotides (AS ODNs) are short, syn-</text>
<text top="681" left="315" width="240" height="9" font="font13" id="p1_t74" reading_order_no="72" segment_no="22" tag_type="text">thetic stretches of DNA that hybridize with specific mRNA</text>
<text top="705" left="57" width="498" height="7" font="font3" id="p1_t75" reading_order_no="73" segment_no="23" tag_type="footnote">ANOVA = analysis of variance; AS = antisense; CREB = cyclic-AMP-responsive element-binding protein; DMSO = dimethyl sulfoxide; DOX = dox-<i>Bcl-2 </i></text>
<text top="715" left="57" width="499" height="7" font="font3" id="p1_t76" reading_order_no="74" segment_no="23" tag_type="footnote">orubicin; ER = estrogen receptor; IL = interleukin; LSD = least significant difference; MM = mismatch control; MTT = 3-(4,5-dimethylthiazol-2-yl)-2,5-</text>
<text top="724" left="57" width="499" height="7" font="font3" id="p1_t77" reading_order_no="75" segment_no="23" tag_type="footnote">diphenyl-2 H -tetrazolium bromide; ODN = oligodeoxynucleotide; PARP = poly(ADP-ribose) polymerase; RC = random control; TXL = paclitaxel; TXT</text>
<text top="734" left="57" width="190" height="7" font="font3" id="p1_t78" reading_order_no="76" segment_no="23" tag_type="footnote">= docetaxel; VDAC = voltage-dependent anion channel.</text>
</page>
</pdf2xml>
